治疗前68[Ga]Ga-DOTA-TATE PET/CT体积参数对高分化神经内分泌肿瘤长效生长抑素类似物治疗反应的预测价值
本研究回顾性纳入42例组织学确诊的转移性神经内分泌肿瘤患者,在长效生长抑素类似物一线治疗前行68[Ga]Ga-DOTA-TATE PET/CT,测量SUV及体积参数。中位无进展生存期26.5个月、总生存期46.5个月;Tmean/Smean比值、Ki-67指数及治疗前嗜铬粒蛋白A血清浓度与无进展生存期显著相关,体积参数与总生存期无显著相关。结论认为治疗前体积参数可能有助于预测生长抑素类似物治疗反应。
要点
- Tmean/Smean比值(HR 1.88,95%CI 1.06-3.35,p=0.03)与无进展生存期显著相关。
- Ki-67指数(HR 1.14,95%CI 1.03-1.26,p=0.01)与无进展生存期显著相关。
- 小肠神经内分泌肿瘤中TSTV(<125.85 cm3 vs ≥125.85 cm3,p=0.023)与无进展生存期显著相关。
核心结论
- 治疗前68[Ga]Ga-DOTA-TATE PET/CT体积参数可能有助于预测神经内分泌肿瘤患者对一线单药生长抑素类似物治疗的反应。
研究设计与样本
- 回顾性研究纳入42例组织学确诊的转移性神经内分泌肿瘤患者(女性21例、男性21例,年龄范围46-84岁;G1 13例、G2 28例;中位Ki-67指数5%,范围1-16)。
- 患者均接受长效生长抑素类似物作为一线治疗,并在治疗前行68[Ga]Ga-DOTA-TATE PET/CT。
- 测量所有68[Ga]Ga-DOTA-TATE高摄取病灶的SUVmax、SUVmean、生长抑素受体表达肿瘤体积(STV)、总病灶生长抑素受体表达(TLD,STV乘以SUVmean)及Tmean/Smean(肿瘤/转移灶SUVmean除以正常脾脏SUVmean),并计算每例患者STV总和(TSTV)与TLD总和(TTLD)。
主要发现
- 研究期间14例(33.3%)疾病稳定,28例(66.7%)出现进展,其中12例死亡。
- 中位无进展生存期为26.5个月,中位总生存期为46.5个月。
- 全人群多因素分析中,Tmean/Smean比值(HR 1.88,95%CI 1.06-3.35,p=0.03)、Ki-67指数(HR 1.14,95%CI 1.03-1.26,p=0.01)及治疗前嗜铬粒蛋白A血清浓度(HR 1.01,95%CI 1.0-1.03,p=0.01)与无进展生存期显著相关。
- 小肠神经内分泌肿瘤患者单因素分析中,TSTV(<125.85 cm3 vs ≥125.85 cm3,p=0.023)和TTLD(<4168.95 vs ≥4168.95,p=0.026)与无进展生存期显著相关。
- 所测体积参数与总生存期无显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over the past decade, numerous treatment options have emerged for patients with locally advanced and metastatic neuroendocrine tumours (NETs). Nevertheless, the optimal timing of treatment interventions remains uncertain, given the highly variable disease course observed in these patients, even when patients have the same tumour stage and grade. The aim of the study was to evaluate the predictive role of standardized uptake values (SUVs) and volumetric parameters obtained from pretreatment [68Ga]Ga-DOTA-TATE for response to SSA therapy in patients with NET. In this retrospective study, we included 42 patients (21 women, 21 men; age range: 46-84 years) with histologically confirmed, metastatic, NET (G1 13, G2 28 cases); median Ki-67 index 5%, range 1-16) who received long acting SSA as a first line treatment and underwent [68Ga]Ga-DOTA-TATE PET/CT before SSA treatment. For all [68Ga]Ga-DOTA-TATE avid lesion SUVmax, SUVmean, somatostatin receptor expression tumour volume (STV), total lesion somatostatin receptor expression (TLD, STV multiplied by SUV mean) and Tmean/Smean (SUVmean of tumours/metastases divided by SUVmean of normal spleen) were measured. Finally, the sum of STV (total STV, TSTV) and TLD (total TLD, TTLD) was calculated for each patient and used in the analysis. RESULTS: During the study period, 14 patients had stable disease (33.3%) and 28 patients experienced progression (66.7%), among whom 12 patients died. The median progression-free survival (PFS) and overall survival (OS) were 26.5 and 46.5 months, respectively. In the univariate and multivariate analysis, in the whole population study, Tmean/Smean ratio (HR 1.88, 95% CI 1.06-3.35, p = 0.03), Ki-67 index (HR 1.14, CI 1.03-1.26, p = 0.01) and pre-treatment chromogranin A serum concentration (HR 1.01, CI 1.0-1.03, p = 0.01) were significantly associated with PFS. Among patients with small intestinal NETs, TSTV (< 125.85 cm3 vs. ≥ 125.85 cm3, p = 0.023) and TTLD (< 4168.95 vs. ≥ 4168.95, p = 0.026) were significantly associated with PFS in the univariate analyses. No significant correlation was found between measured volumetric parameters and OS. CONCLUSION: Volumetric parameters of pretreatment 68[Ga]Ga-DOTA-TATE PET/CT may be useful in prediction of the response to SSA (used in monotherapy as a first-line therapy) in patients with NET.
引用
- Morawiec-Sławek K, Opalińska M, Lenda-Tracz W, et al. Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours. EJNMMI Res. 2024. PMID: 39538103. doi:10.1186/s13550-024-01169-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。